Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges.
about
Advances in mass spectrometry-based clinical biomarker discoveryGarbage in, garbage out: a critical evaluation of strategies used for validation of immunohistochemical biomarkersBiomarkers in prostate cancer: what's new?Precision medicine: from pharmacogenomics to pharmacoproteomicsProof-of-Concept Workflow for Establishing Reference Intervals of Human Urine Proteome for Monitoring Physiological and Pathological Changes.Nanoparticle Probes for the Detection of Cancer Biomarkers, Cells, and Tissues by FluorescenceMultiplex Immunosensor Arrays for Electrochemical Detection of Cancer Biomarker Proteins.Biomarkers of HIV-associated Cancer.Insufficient antibody validation challenges oestrogen receptor beta research.Validation of a blood protein signature for non-small cell lung cancerUse of autoantibodies to detect the onset of breast cancerBiomarkers of PTSD: military applications and considerations.Label-free LC-MSe in tissue and serum reveals protein networks underlying differences between benign and malignant serous ovarian tumors.Immunohistochemical quantification of the cobalamin transport protein, cell surface receptor and Ki-67 in naturally occurring canine and feline malignant tumors and in adjacent normal tissuesSerial analysis of 38 proteins during the progression of human breast tumor in mice using an antibody colocalization microarray.Improving the quality of biomarker discovery research: the right samples and enough of themA signaling visualization toolkit to support rational design of combination therapies and biomarker discovery: SiViT.KLHL21, a novel gene that contributes to the progression of hepatocellular carcinomaInteraction of Serum Antibodies from Breast Cancer Patients with Synthetic Peptides.Electrochemistry-based approaches to low cost, high sensitivity, automated, multiplexed protein immunoassays for cancer diagnosticsCancer biomarker discovery using DNA aptamers.Biomarkers for Bone Tumours: Discovery from Genomics and Proteomics Studies and Their Challenges.Adsorbing/dissolving Lyoprotectant Matrix Technology for Non-cryogenic Storage of Archival Human SeraBiomarker discovery in mass spectrometry-based urinary proteomics.A Multiplexed Cytokeratin Analysis Using Targeted Mass Spectrometry Reveals Specific Profiles in Cancer-Related Pleural EffusionsFibrinogen alpha C chain 5.9 kDa fragment (FIC5.9), a biomarker for various pathological conditions, is produced in post-blood collection by fibrinolysis and coagulation factors.Clinical proteomic biomarkers: relevant issues on study design & technical considerations in biomarker development.MRM for the verification of cancer biomarker proteins: recent applications to human plasma and serum.Cancer biomarker discovery: current status and future perspectives.Mass spectrometry based biomarker discovery, verification, and validation--quality assurance and control of protein biomarker assays.Proteomic analyses of CSF aimed at biomarker development for pediatric brain tumors.Advances in urinary proteome analysis and applications in systems biology.Important options available--from start to finish--for translating proteomics results to clinical chemistry.CE-MS-based proteomics in biomarker discovery and clinical application.Relative versus absolute quantitation in disease glycomics.Epidemiologic design and analysis for proteomic studies: a primer on -omic technologies.Biomarker Qualification: Toward a Multiple Stakeholder Framework for Biomarker Development, Regulatory Acceptance, and Utilization.Recent findings from the Human Proteome Project: opening the mass spectrometry toolbox to advance cancer diagnosis, surveillance and treatment.Cancer proteomics: developments in technology, clinical use and commercialization.Transition from identity to bioactivity-guided proteomics for biomarker discovery with focus on the PF2D platform.
P2860
Q26770004-F25464EC-F662-4C74-A36E-2E490DEF87F3Q27001445-9686B015-E1A0-4C3F-BFFB-F80F811BAE33Q27026210-C29631ED-37E5-4443-907C-62DA40623A7FQ28076871-7EA104A8-E5D5-40CE-B8E9-6CEB85022829Q33603691-2F4926C0-25B8-4093-8ADD-7E763E495188Q33759991-B421A4CE-E4AA-4356-8A66-4E7E8AF173C4Q33764870-6DB47EE8-AE09-42E1-B407-04D4ADFE4BDAQ33856851-39FA2FD2-BEA9-474B-A793-8908006462B3Q33885342-9765DAC1-17D3-43CB-A8DB-0069BE1127ECQ34008245-F71D2B67-9830-4DE9-B424-4762F1B4E3C9Q34037876-5875025F-39DB-4146-8201-BE6BDBA129BDQ34068752-B0D51867-0661-4B63-943F-2F2E0E017DC8Q34267969-2B490C9B-DCC6-4523-BA8E-CB17BCDAEA88Q35273633-1FE0F0D4-1AC7-4A9A-A577-4C88C72D377FQ35325472-E4EF9CF5-7D73-4D2D-824D-C5CB02032B99Q35674848-398368FB-B020-481C-84A8-0AE204E8C42AQ36052565-34A398CE-FE70-45DC-9FF2-BF062A30BA9AQ36171505-631F3D8B-BACE-4F47-9AC7-176906AD7AE9Q36174786-725818D6-6B86-4377-AF8C-FB475D5EF18CQ36430835-320DE0A3-8C1F-4FF7-8F21-85D1FB04D9B4Q36430991-D2124517-D6D2-42F7-9291-D7BBA4106A21Q36758011-4CE38D4A-6122-4F05-BF7B-26D49C4BA732Q36789976-73608262-9702-43DB-AE4E-EA6E22CFF546Q36956324-B94B9631-4ECE-4F92-ACC2-A338471305BCQ37112709-FEA7D99C-D4DE-414B-8110-C3D9C26853E9Q37322221-8D7B0754-F163-4E84-9DF7-7D53EE3157D3Q37714579-BEE8EAE2-0EFD-4340-B961-9FDEAB6C9954Q38183147-7367BEB9-0E80-4526-A0EE-3C226FE2D5BAQ38187679-742B6E66-DE93-4858-BE5F-8A91A28EF8CFQ38203040-823A0A82-F473-431F-AEE6-1E4A31DFF7FBQ38207538-69B7DE1B-968F-44DF-8DA9-18DDFE3C186BQ38269864-AF862694-4FE7-4E36-A9C0-300F8F287C9BQ38282797-100C2FB4-DE88-421C-A7A0-05F129A207FFQ38340358-9C1DDA9B-6457-4ACB-B99D-067A51A95399Q38356585-301DF5C4-3A10-4CA1-B5EA-7E89871D2DCFQ38384848-DCA09667-BB9D-453C-B95A-59BCA1F312C6Q38418590-4BB07E94-68F4-4938-AA01-E51CBEC3E200Q38449763-68EC25D1-1242-444E-A996-FE8EE66DEE05Q38543009-9E2DBF75-70F1-4BF0-800D-123AB0FB8D60Q38552059-170AEF82-DF65-4720-9A0C-AED00020FEFD
P2860
Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges.
description
2013 թվականի հոկտեմբերի 2-ին հրատարակված գիտական հոդված
@hy
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 02 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
name
Translation of proteomic bioma ...... ostics: issues and challenges.
@en
Translation of proteomic bioma ...... ostics: issues and challenges.
@nl
type
label
Translation of proteomic bioma ...... ostics: issues and challenges.
@en
Translation of proteomic bioma ...... ostics: issues and challenges.
@nl
prefLabel
Translation of proteomic bioma ...... ostics: issues and challenges.
@en
Translation of proteomic bioma ...... ostics: issues and challenges.
@nl
P2093
P2860
P356
P1433
P1476
Translation of proteomic bioma ...... ostics: issues and challenges.
@en
P2093
Anna K Füzéry
Daniel W Chan
Joshua Levin
Maria M Chan
P2860
P2888
P356
10.1186/1559-0275-10-13
P577
2013-10-02T00:00:00Z